Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina. Show more
3901 Barrett Drive, Raleigh, NC, 27609, United States
Market Cap
438.2M
52 Wk Range
$12.95 - $38.41
Previous Close
$29.50
Open
$28.93
Volume
164,748
Day Range
$24.06 - $28.93
Enterprise Value
438.5M
Cash
193K
Avg Qtr Burn
N/A
Insider Ownership
4.74%
Institutional Own.
12.98%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Mizagliflozin Details Recurrent postprandial hypoglycemia following Roux-en-Y bariatric surgery | Phase 2b Data readout |